Skip to main content
Disc Medicine, Inc. logo

Disc Medicine, Inc. — Investor Relations & Filings

Ticker · IRON ISIN · US36870G1058 US Manufacturing
Open in API
Filings indexed 690 across all filing types
Latest filing 2024-11-20 Regulatory Filings
Country US United States of America
Listing US IRON

About Disc Medicine, Inc.

https://www.discmedicine.com/

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients with serious hematologic diseases. The company's research focuses on fundamental pathways of red blood cell biology to address a range of disorders. Its pipeline includes bitopertin, an investigational therapy for erythropoietic protoporphyria (EPP) for which a New Drug Application has been submitted for accelerated approval. Other clinical-stage programs are evaluating treatments for myelofibrosis-associated anemia and other conditions involving ineffective erythropoiesis.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings
2024-11-20 English
4
Director's Dealing
2024-11-20 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a Controlled Equity Offering Sales Agreement for common stock. It details terms of a stock offering, sales agent information, compensation, risk factors, and use of proceeds. This type of document is a capital raising disclosure, specifically a prospectus supplement for a stock offering. It is not a financial report, earnings release, or management discussion. It is a detailed announcement of a financing activity involving new share issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a regulatory filing fallback. Confidence is high due to clear identification of offering terms and regulatory references to Securities Act and Rule 424(b)(5).
2024-11-15 English
POS AM
Regulatory Filings Classification · 100% confidence The document is titled 'Post-Effective Amendment No. 1 to Form S-3 Registration Statement' filed with the SEC. It references the Securities Act of 1933 and discusses deregistration of unsold securities under a previously effective registration statement. The content is regulatory in nature, related to securities registration and deregistration, and does not contain financial statements, earnings data, or management discussion. It is a formal amendment to a registration statement, which is a regulatory filing. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length (6310 characters) and content confirm it is not a full financial report or earnings release but a regulatory amendment filing.
2024-11-15 English
Regulatory Filings 2024
Regulatory Filings
2024-11-15 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a Controlled Equity Offering Sales Agreement and the termination of a prior sales agreement, both related to the company's capital raising activities. There are no financial statements or detailed financial performance data presented, only disclosures about financing agreements and sales of shares. This fits the definition of a Capital/Financing Update (CAP) rather than an Annual Report, Earnings Release, or other report types. The document length is 7308 characters, which is sufficient for a detailed announcement but does not contain comprehensive financial data or management discussion. Therefore, the correct classification is CAP with high confidence.
2024-11-15 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.